IL267219B2 - New oral dosage forms with immediate and variable release of tefenam pivoxil - Google Patents

New oral dosage forms with immediate and variable release of tefenam pivoxil

Info

Publication number
IL267219B2
IL267219B2 IL267219A IL26721919A IL267219B2 IL 267219 B2 IL267219 B2 IL 267219B2 IL 267219 A IL267219 A IL 267219A IL 26721919 A IL26721919 A IL 26721919A IL 267219 B2 IL267219 B2 IL 267219B2
Authority
IL
Israel
Prior art keywords
tebipenem pivoxil
dosage form
tablet core
tebipenem
hbr
Prior art date
Application number
IL267219A
Other languages
English (en)
Hebrew (he)
Other versions
IL267219B1 (en
IL267219A (en
Original Assignee
Spero Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spero Therapeutics Inc filed Critical Spero Therapeutics Inc
Publication of IL267219A publication Critical patent/IL267219A/en
Publication of IL267219B1 publication Critical patent/IL267219B1/en
Publication of IL267219B2 publication Critical patent/IL267219B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL267219A 2016-12-15 2017-12-15 New oral dosage forms with immediate and variable release of tefenam pivoxil IL267219B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662434643P 2016-12-15 2016-12-15
US201662438071P 2016-12-22 2016-12-22
PCT/US2017/066729 WO2018112372A1 (en) 2016-12-15 2017-12-15 Novel tebipenem pivoxil immediate and modified release oral dosage forms

Publications (3)

Publication Number Publication Date
IL267219A IL267219A (en) 2019-08-29
IL267219B1 IL267219B1 (en) 2024-09-01
IL267219B2 true IL267219B2 (en) 2025-01-01

Family

ID=60937949

Family Applications (1)

Application Number Title Priority Date Filing Date
IL267219A IL267219B2 (en) 2016-12-15 2017-12-15 New oral dosage forms with immediate and variable release of tefenam pivoxil

Country Status (15)

Country Link
US (2) US12226403B2 (enExample)
EP (2) EP3554484B1 (enExample)
JP (2) JP7083828B2 (enExample)
KR (1) KR102640532B1 (enExample)
CN (2) CN115192533A (enExample)
AU (2) AU2017377062B2 (enExample)
BR (1) BR112019012171B1 (enExample)
CA (1) CA3045566C (enExample)
CO (1) CO2019006183A2 (enExample)
ES (1) ES3037252T3 (enExample)
IL (1) IL267219B2 (enExample)
MX (3) MX2019007136A (enExample)
PH (1) PH12019501234A1 (enExample)
WO (1) WO2018112372A1 (enExample)
ZA (1) ZA201903309B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115192533A (zh) 2016-12-15 2022-10-18 斯派尔治疗有限公司 新型替比培南匹伏酯速释和调释口服剂型
JP7309607B2 (ja) 2017-02-06 2023-07-18 スペロ セラピューティックス，インコーポレイテッド テビペネムピボキシル臭化水素酸塩の結晶形、および医薬組成物
CN109432044B (zh) * 2018-11-27 2021-05-11 山东省药学科学院 一种替比培南酯细粒剂及其制备方法
EP4243783A1 (en) * 2020-11-11 2023-09-20 Spero Therapeutics, Inc. High dosage tebipenem pivoxil tablet formulation
CN115969815A (zh) * 2023-02-10 2023-04-18 鲁南贝特制药有限公司 一种替比培南酯口服制剂及其制备方法
CN118526466B (zh) * 2024-07-22 2024-11-05 山东则正医药技术有限公司 一种替比培南匹伏酯颗粒制剂及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102860985A (zh) * 2011-07-06 2013-01-09 石药集团中奇制药技术（石家庄）有限公司 一种泰比培南酯口服制剂及其制备方法
CN102885811A (zh) * 2012-08-27 2013-01-23 南京华威医药科技开发有限公司 含有泰比培南酯的口服制剂
CN103371977A (zh) * 2012-04-25 2013-10-30 秦引林 一种泰比培南酯颗粒及其制备方法
CN103655483A (zh) * 2012-09-26 2014-03-26 扬州市星斗药业有限公司 一种含有替比培南的颗粒及其制备方法
CN104013583A (zh) * 2014-06-27 2014-09-03 深圳致君制药有限公司 一种泰比培南酯组合物的药物制剂及其制备方法
CN105997891A (zh) * 2016-05-20 2016-10-12 郑州明泽医药科技有限公司 一种替比培南酯制剂及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
AU682510B2 (en) * 1993-07-01 1997-10-09 Pfizer Japan Inc. 2-(1-(1,3-thiazolin-2-yl)azetidin-3-yl)thio-carbapenem derivatives
JP3317604B2 (ja) 1994-12-28 2002-08-26 日本ワイスレダリー株式会社 結晶形態のカルバペネム化合物
TW420681B (en) 1995-12-08 2001-02-01 Lederle Japan Ltd Carbapenem-3-carboxylic acid ester derivatives
JP2847093B2 (ja) 1996-03-11 1999-01-13 ソニー株式会社 ビデオカメラ
JP3317649B2 (ja) 1997-01-13 2002-08-26 日本ワイスレダリー株式会社 結晶形態のカルバペネム化合物
JP2003171277A (ja) 2001-12-07 2003-06-17 Wyeth Lederle Japan Ltd 薬物放出時間制御型固形製剤
AU2003211146B2 (en) * 2002-02-21 2007-07-19 Valeant International (Barbados) Srl Controlled release dosage forms
JP2004035517A (ja) 2002-07-08 2004-02-05 Wyeth Lederle Japan Ltd カルバペネム系抗生剤含有経口製剤
JP2004035518A (ja) 2002-07-08 2004-02-05 Wyeth Lederle Japan Ltd 苦味をマスキングしたカルバペネム系抗生剤含有経口顆粒製剤
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
WO2007070164A1 (en) * 2005-10-19 2007-06-21 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same
US20080069879A1 (en) 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
JP2011504495A (ja) 2007-11-23 2011-02-10 クジェ ファーマシューティカル インダストリアル カンパニー リミテッド ２−アリールメチルアゼチジン−カルバペネム−３−カルボン酸エステル誘導体またはその塩、その製造方法及びそれを含む医薬組成物
KR100950699B1 (ko) 2008-03-28 2010-03-31 국제약품공업주식회사 2-아릴메틸아제티딘-카바페넴-3-카복실산 에스테르유도체의 산부가염, 이의 제조방법 및 이를 포함하는 약학조성물
CN102558181B (zh) * 2010-12-15 2015-04-22 石药集团中奇制药技术（石家庄）有限公司 一种碳青霉烯抗生素的制备方法
CN102731507B (zh) 2011-04-13 2015-04-01 石药集团中奇制药技术（石家庄）有限公司 泰比培南晶型、其制备方法及其在制备药物中的应用
CN102276611B (zh) 2011-05-18 2013-01-09 深圳万乐药业有限公司 一种替比培南酯的重结晶精制方法
CN103664948B (zh) 2012-09-05 2015-12-16 凌沛学 一种替比培南酯的中间体的结晶及其制备方法
CN103664949A (zh) 2012-09-12 2014-03-26 高瑞耀业(北京)科技有限公司 替比培南匹伏酯结晶及其制备方法
CN102836130A (zh) 2012-09-19 2012-12-26 山东罗欣药业股份有限公司 一种替比培南匹伏酯颗粒剂
CN103054815B (zh) * 2013-02-04 2015-12-02 南京卡文迪许生物工程技术有限公司 替比培南酯口服固体制剂及其制备方法
CN104224725A (zh) 2013-06-14 2014-12-24 北京济美堂医药研究有限公司 一种替比培南酯颗粒剂及其制备方法
CN104027310B (zh) 2013-12-26 2016-02-03 青岛大学 一种法罗培南钠颗粒剂及其制备方法
CN105193742A (zh) 2015-10-30 2015-12-30 海口市制药厂有限公司 替比培南酯颗粒剂组合物、其制备方法及应用
CN105963261A (zh) * 2016-07-08 2016-09-28 河南全宇制药股份有限公司 一种替比培南酯颗粒剂及其制备方法
CN115192533A (zh) 2016-12-15 2022-10-18 斯派尔治疗有限公司 新型替比培南匹伏酯速释和调释口服剂型
JP7309607B2 (ja) 2017-02-06 2023-07-18 スペロ セラピューティックス，インコーポレイテッド テビペネムピボキシル臭化水素酸塩の結晶形、および医薬組成物
CN107737107B (zh) 2017-12-02 2020-05-29 北京达因高科儿童药物研究院有限公司 一种含替比培南酯组合物的口服制剂及其制备方法
EP4243783A1 (en) 2020-11-11 2023-09-20 Spero Therapeutics, Inc. High dosage tebipenem pivoxil tablet formulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102860985A (zh) * 2011-07-06 2013-01-09 石药集团中奇制药技术（石家庄）有限公司 一种泰比培南酯口服制剂及其制备方法
CN103371977A (zh) * 2012-04-25 2013-10-30 秦引林 一种泰比培南酯颗粒及其制备方法
CN102885811A (zh) * 2012-08-27 2013-01-23 南京华威医药科技开发有限公司 含有泰比培南酯的口服制剂
CN103655483A (zh) * 2012-09-26 2014-03-26 扬州市星斗药业有限公司 一种含有替比培南的颗粒及其制备方法
CN104013583A (zh) * 2014-06-27 2014-09-03 深圳致君制药有限公司 一种泰比培南酯组合物的药物制剂及其制备方法
CN105997891A (zh) * 2016-05-20 2016-10-12 郑州明泽医药科技有限公司 一种替比培南酯制剂及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAKASHIMA M. ET AL.:, EFFECT OF PROBENECID OR DIET ON TEBIPENEM PIVOXIL TABLETS PHARMACOKINETICS IN HEALTHY MALE VOLUNTEERS, 20 March 2009 (2009-03-20) *
STAHL P. H, PREPARATION OF WATER-SOLUBLE COMPOUNDS THROUGH SALT FORMATION, 31 December 2003 (2003-12-31) *

Also Published As

Publication number Publication date
AU2020281095B2 (en) 2022-10-06
AU2017377062A1 (en) 2019-06-06
JP7431886B2 (ja) 2024-02-15
US12226403B2 (en) 2025-02-18
AU2017377062B2 (en) 2020-09-03
ZA201903309B (en) 2020-09-30
EP3554484A1 (en) 2019-10-23
US20250009718A1 (en) 2025-01-09
BR112019012171A2 (pt) 2019-12-17
JP7083828B2 (ja) 2022-06-13
JP2022116261A (ja) 2022-08-09
KR102640532B1 (ko) 2024-02-26
BR112019012171B1 (pt) 2021-02-09
CA3045566C (en) 2024-04-09
MX2022006971A (es) 2022-07-13
CA3045566A1 (en) 2018-06-21
AU2020281095A1 (en) 2021-01-07
EP3554484B1 (en) 2025-05-14
JP2020511419A (ja) 2020-04-16
US20200016126A1 (en) 2020-01-16
IL267219B1 (en) 2024-09-01
NZ753713A (en) 2021-09-24
MX2022014095A (es) 2022-12-08
EP4032531A1 (en) 2022-07-27
MX2019007136A (es) 2019-09-27
CN115192533A (zh) 2022-10-18
PH12019501234A1 (en) 2019-10-07
KR20190097109A (ko) 2019-08-20
CN110072520A (zh) 2019-07-30
IL267219A (en) 2019-08-29
CO2019006183A2 (es) 2019-08-30
WO2018112372A1 (en) 2018-06-21
ES3037252T3 (en) 2025-09-30

Similar Documents

Publication Publication Date Title
AU2020281095B2 (en) Novel tebipenem pivoxil immediate and modified release oral dosage forms
US12350246B2 (en) Eflornithine and sulindac, fixed dose combination formulation
GB2414668A (en) Sustained release delivery system for tetracycline compounds
US10702520B1 (en) Pharmaceutical compositions of posaconazole
US20100178333A1 (en) Sustained release dosage form of phenothiazine derivatives containing channelizer
KR101157486B1 (ko) 경구용 항미생물성 제약학적 조성물
HK40081204A (en) Novel tebipenem pivoxil hbr tablet
NZ753713B2 (en) Novel tebipenem pivoxil immediate and modified release oral dosage forms
EA044993B1 (ru) Лекарственная форма с немедленным высвобождением для перорального применения, содержащая тебипенем пивоксил
TWI743059B (zh) 二氟甲基鳥氨酸及舒林酸（ｓｕｌｉｎｄａｃ），固定劑量組合調配物
WO2024134180A1 (en) Novel composition
US20210361582A1 (en) Colchicine salicylate derivatives and methods of treatment